Provided by Tiger Fintech (Singapore) Pte. Ltd.

ORUKA THERAPEUTICS INC

14.25
+0.02000.14%
Post-market: 14.250.00000.00%17:20 EDT
Volume:70.22K
Turnover:992.53K
Market Cap:533.53M
PE:-4.68
High:14.35
Open:14.25
Low:13.70
Close:14.23
Loading ...

Company Profile

Company Name:
ORUKA THERAPEUTICS INC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
28
Office Location:
855 Oak Grove Avenue,Suite 100,Menlo Park,California,United States
Zip Code:
94025
Fax:
- -
Introduction:
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

Directors

Name
Position
Lawrence Otto Klein
Director, President and Chief Executive Officer
Samarth Kulkarni
Chairman
Cameron Turtle, D.Phil
Independent Director
Carl Dambkowski
Independent Director
Kristine M. Ball
Independent Director
Peter Harwin
Independent Director

Shareholders

Name
Position
Lawrence Otto Klein
Director, President and Chief Executive Officer
Laura Sandler
Chief Operating Officer
Arjun Agarwal
Senior Vice President, Finance and Treasurer
Joana Goncalves
Chief Medical Officer
Paul T. Quinlan
General Counsel and Corporate Secretary